BACKGROUND: The aim of the present study was to evaluate the efficacy of tertiary and quaternary cytoreduction in recurrent @entity43 @entity1 . @entity1 AND METHODS: Between January 1997 and December 2014, 53 @entity1 were submitted to cytoreductive surgery for second and third @entity43 recurrence at our Unit. RESULTS: Median age at first diagnosis was 48 years (range=20-69). Forty-six @entity1 (86.8%) underwent tertiary cytoreduction. At the time of surgery, isolated and diffuse disease was observed in 48 (90.6%) and 5 (9.4%) @entity1 , respectively. Complete and optimal cytoreduction was obtained in 41 (77.5%) and in 1 (1.9%) @entity1 , respectively. We did not observe any statistically significant survival differences according to @entity41 . @entity1 with TFI >12 months showed longer PFS (38 vs. 7 months, p<0.002) than those with TFI <12 months. In 18 of these @entity1 a third recurrence was observed. In 12 @entity1 (66.7%) a complete quaternary cytoreduction was performed. Longer PFS (16 vs. 21 months; p=0.032) and @entity3012 (152 vs. 116 months; p=0.015) in @entity1 submitted to cytoreduction with respect to those treated with chemotherapy were observed. CONCLUSION: Our data suggest that selected @entity43 @entity1 who develop a secondary and tertiary recurrence may benefit from additional cytoreductive attempts. The benefit seems to be greater in @entity1 with TFI >12 months showing a single-site recurrence disease, in which complete cytoreduction is achievable. Further studies are required to better-define the role of tertiary and quaternary cytoreduction in recurrent @entity43 @entity1 .

Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent XXXX ?

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS']
@entity43 :: (MESH:D010051,Disease) :: ['Ovarian Cancer']
